Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3022855 in advanced breast or prostate cancer
NCT02265536Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2015
- Primary completion
- Nov 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of LY3022855 in breast cancer and prostate cancer (PCa) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Percentage Change From Baseline in Peripheral Blood Immune Cell Subsets at Day 8, Percentage Change From Baseline in Serum Cytokines at Day 8 and 1 more. Started May 2015; status: completed.
02
Drugs
LY3022855
03
Conditions
breast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT02265536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02265536.